Dr. Billings has devoted his life to studying and teaching medicine and genetics, while accelerating the use of a broad range of novel genomic technologies in clinical settings. Over his decades in healthcare, he has established key business partnerships, driving adoption of innovative discoveries and commercial success. His leadership is backed by notable achievements—physician, researcher, founder, senior executive or director of multiple public and private companies, and scientific advisor for government entities.

Dr. Billings has held academic appointments at Harvard University, U.C. San Francisco, Stanford University, and U.C. Berkeley; and served as a board-certified internist and medical geneticist at leading medical centers. His published doctoral studies at Harvard were supervised by Dr. Baruj Benacerraf who subsequently received the Nobel Prize in Medicine. In addition, he has served on the Scientific Advisory Board of the Food and Drug Administration (FDA), the Genomic Medicine Advisory Committee at the Department of Veterans Affairs, and as an appointee to the Secretary’s Advisory Committee on Genetics, Health, and Society at the Department of Health and Human Services. Previously, he has been Chief Medical Officer or Senior Physician at Laboratory Corporation of America Holdings, Life Technologies Corp, Thermo Fisher Scientific Inc., and Natera, Inc.

Dr. Sanjay Jha brings a wealth of knowledge and experience in systems, software, semiconductors and technology investments. He began his career leading design engineering teams in San Diego and London before moving on to Qualcomm where his engineering roles included Senior Engineer, Vice President and Senior Vice President. Dr. Jha was instrumental in the formation of Qualcomm Technologies and Ventures, where he led the technology group and investment portfolio in executive leadership roles, followed by his tenure as president and COO of Qualcomm CDMA Technologies. He continued his career as COO for Motorola Mobile Devices and CEO, Motorola Mobility prior to being appointed Chairman and CEO of GLOBALFOUNDRIES, the second largest semiconductor foundry business in the world.

Dr. Jha has served on the Semiconductor Industry Association Board of Directors, and as Vice-Chairman of the Fabless Semiconductor Association (now the Global Semiconductor Alliance (GSA). In 2011 Sanjay was awarded the honorary degree of DSc by the University of Strathclyde, and in 2018 he was inducted into United States National Academy of Engineering.

Dr. Jha received his BS in electrical engineering from the University of Liverpool and PhD in electronics engineering from the University of Strathclyde, Glasgow, Scotland.

Mr. Miller is an accomplished executive with a proven track record of developing and growing global life science businesses, most notably at Life Technologies (now ThermoFisher Scientific) and BD Biosciences.

Until 2011, he served as President of the Genetic Systems at Life Technologies, an approximately $1B division of a market-leading provider of DNA sequencing systems developed for academic research, applied market segments for human identification, and clinical diagnostics. Prior to the formation of Life Technologies, Kip served as Senior Vice President of Invitrogen (2005-2008) where he led the $500M Biodiscovery division, a leading developer of life science tools and enabling technologies for biomedical research, pharmaceutical drug discovery services, and transplantation diagnostics. Earlier in his career Mr. Miller held a variety of responsibilities at BD Biosciences including General Manager and Vice President of Sales and Services of the Americas.

Mr. Miller is actively involved with early life sciences companies. He is a former board member of Tonbo Biosciences (co-founder), Solulink, Cellector, Celsee, and Firefly Bioworks.

Mr. Maier brings strong senior operational and financial experience, as well as an impressive track record of shaping and expanding life science businesses, to the Biological Dynamics board. He has over 25 years of experience as a senior executive in biotechnology and pharmaceutical companies, where he raised more than $1.5 billion in equity and debt financing and led a number of IPO and M&A transactions.

As Chief Financial Officer of Sequenom, Inc. from November 2009 through June 2014, Mr. Maier was instrumental in raising more than $360 million in equity and debt financing and commercializing Sequenom’s molecular diagnostics segment. He served as Chief Financial Officer at Ligand Pharmaceuticals Inc. from 1992 to 2007 where he helped build the venture-stage company into a commercial, integrated biopharmaceutical organization and ICN Pharmaceuticals (now Valeant Pharmaceuticals International, Inc.) where he served in various senior finance and general management roles.

Mr. Maier currently serves on the Board of Apricus Biosciences, International Stem Cell, MabVax Therapeutics, and Ritter Pharmaceuticals.

Mr. Maier received an MBA from Harvard Business School and a BS from Pennsylvania State University.

Mr. Russell brings to Biological Dynamics more than 30 years of experience as the head of finance in emerging companies. He has been associated with both private and public companies leading all aspects of the finance and administration function, including accounting, treasury, financial planning and budgeting, risk management and information systems. He has served in this capacity at various companies such as HNC Software (now Fair Isaac Corporation), Enevate Corporation, MaxLinear Inc., American Technology Corporation, Cerwin-Vega, Inc., Metallic Power, Inc., and Vitesse Semiconductor Corporation. For the past 15 years he has provided consulting services to rapidly growing companies.

Mr. Russell received his BSEE degree from the Samueli School of Engineering at UCLA and an MBA degree from the UCLA Anderson School of Management.